An Exploratory Study of MT-2990 in Patients With AAV

NCT06196905 | Completed Phase 1 FDA Drug

• 2 other identifiers: MT-2990-C-101jRCT2031230538
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 8

Brief Summary

To explore the efficacy, safety, pharmacokinetics and mechanism of action of MT-2990 in patients with AAV.

Conditions

Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)

Outcome Measures

Primary Outcomes (14)

• Change from baseline in Birmingham Vasculitis Activity Score (BVAS) at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed. Birmingham Vasculitis Activity Score (BVAS) form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health).

  Up to Week 24

• Proportion of subjects who achieve BVAS=0 at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed.

  Up to week 24

• Change from baseline in Vasculitis Damage Index (VDI) at each scheduled timepoints.

  No primary endpoint is used, because various exploratory analyses are performed. Vasculitis Damage Index (VDI) is comprised of 64 items of damage, grouped into 11 organ-based systems or categorizations. Damage is defined as the presence of non-healing scars and does not give any indication of current disease activity. Damage is also defined as having been present or currently present for at least 3 months. Completion of the form provides a numerical score, which ranges from 0 (best health) to 64 (worst health).

  Up to week 24

• Patient Global Impression of Change (PGIC) at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed. Patient Global Impression of Change (PGIC) is a questionnaire to evaluate the overall impression of improvement by patient from 1 (very much improved) to 7 (very much worse). Higher PGIC scores indicated worse outcome.

  Up to week 24

• Clinical Global Impression of Change (CGIC) at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed. Clinician Global Impression of Change (CGIC) a questionnaire to evaluate the overall impression of improvement by clinician from 1 (very much improved) to 7 (very much worse). Higher CGIC scores indicated worse outcome.

  Up to week 24

• Change from baseline in FDG-PET/CT findings at week 24

  No primary endpoint is used, because various exploratory analyses are performed.

  Baseline and week 24

• Change from baseline in chest CT findings at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed.

  Up to week 24

• Change from baseline in head and neck CT/MRI findings at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed.

  Up to week 24

• Change from baseline in respiratory function tests (FVC [mL]) at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed.

  Up to week 24

• Change from baseline in hearing threshold measured by pure-tone audiometry at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed.

  Up to week 24

• Time course of BM {eGFR, urine protein/creatinine ratio (first morning urine), eosinophil count, serum KL-6, CRP, and ANCA-titer (MPO-ANCA, PR3-ANCA)} at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed.

  Up to week 24

• Change in dosage of steroid

  No primary endpoint is used, because various exploratory analyses are performed.

  Up to week 24

• Change from baseline in SF-36 at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed.

  Up to week 24

• Change from baseline in EQ-5D-5L at each scheduled timepoints

  No primary endpoint is used, because various exploratory analyses are performed.

  Up to week 24

Study Arms (1)

MT-2990

EXPERIMENTAL

MT-2990 will be administered intravenously every 4 weeks for a total of 6 doses.

Drug: MT-2990

Interventions

MT-2990 DRUG

i.v. infusion

MT-2990

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged 18 years or older on the day of informed consent
• Clinical diagnosis of microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), or eosinophilic granulomatosis with polyangiitis (EGPA) according to 2022 ACR/EULAR Classification Criteria by the date of informed consent
• Patients who meet at least one of the following criteria 1) or 2)
• \) Patients is judged to be indicative of disease activity by the investigator with disease activity satisfying all of the following criteria at screening. If measurements or tests were performed multiple times during the screening period, the results from the latest date should be used to confirm that the criteria are met.
• I. As elevated CRP due to active AAV, CRP \>= 0.2 mg/dL
• II. BVAS \>= 1
• III. At least one of the findings in a) to e) below. c) is only applicable to patients with EGPA.
• FDG-PET/CT image finding(s) (Grade \>= 2 \[defined as FDG uptake = liver\], and judged that the findings indicate inflammation by radiologist)
• FVC(mL) below the lower limit of normal calculated using the "new reference range for Japanese using LMS method" and KL-6 \>= 500 U/mL
• History or presence of asthma and eosinophils counts \>= 1000/µL
• eGFR \< 60 mL/min/1.73 m 2 and first-morning urine protein/creatinine ratio \> 0.2 g/g Cr
• Presence of hearing loss due to active AAV and air conduction hearing threshold (average of measurements at 0.25,0.5,1, 2, and 4 kHz) \>= 30 dB in at least one ear
• \) Steroid-dependent patients who satisfy the following criteria I and II:
• II. No initiation or increased dose of azathioprine or avacopan since the time of the worsening of the primary disease of I.

You may not qualify if:

• Patients who have manifestations leading to life-threatening or vital organ dysfunction due to AAV, in the opinion of the Investigator.
• Patients with autoimmune diseases or vasculitis other than AAV such as systemic lupus erythematosus, IgA vasculitis, rheumatoid vasculitis, Sjogren's syndrome, anti-glomerular basement membrane nephritis, cryoglobulinemic vasculitis, idiopathic inflammatory muscle disease, systemic sclerosis.
• Patients who are judged by the Investigator to have an improvement trend of active finding(s) for AAV during remission maintenance treatment from the 12 weeks prior to the start of screening to the time of the first dose, and to be expected to improve spontaneously without change of treatment.
• Patients who received rituximab or immunosuppressive biologics (eg., TNF inhibitors) from 12 weeks prior to the start of screening to the time of the first dose.
• Patients who received mepolizumab from 8 weeks prior to the start of screening to the time of the first dose.
• Patients who received cyclophosphamide, methotrexate, mycophenolate mofetil, plasma exchange therapy or other immunosuppressive therapy from 4 weeks prior to screening to the time of the first dose.
• Patients who received a live vaccine from 4 weeks before the date of the first dose to the time of the first dose.
• Patients who have received steroids at prednisolone equivalent doses of more than 20 mg/day, initiated steroids, or increased the dose of steroids from 4 weeks prior to the start of screening to the time of the first dose.
• Exceptionally, only for rituximab treatment failures are allowed to initiate steroids or increase steroids dose up to that of their most recent induction remission therapy (i.e., doses exceeding 20 mg/day of prednisolone equivalent are allowed) until the day before the first dose.
• Patients who have initiated, increased, or decreased the dose of azathioprine from 4 weeks prior to the start of screening to the time of the first dose.
• Patients who have initiated, increased, or decreased the dose of avacopan from 4 weeks prior to the start of screening to the time of the first dose.
• Patients with concomitant or history of hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection unless patients have negative test result of hepatitis B virus surface (HBs) antigen, HBs antibody, and hepatitis B virus core (HBc) antibody at screening, or have maintained a negative HCV-RNA test result for at least 12 weeks after completion of hepatitis C treatment.
• Patients with systemic active infections at the day of screening evaluation or the date of the first dose.
• Patients with a history of malignancy within 5 years prior to the start of screening, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or intraepithelial carcinoma of the cervix who have completed treatment (including therapy other than anticancer agents for the treatment of cancer) without recurrence for at least 1 year.
• History of anaphylaxis or clinically significant allergic symptoms due to administration of antibody products.

Sponsors & Collaborators

• Tanabe Pharma Corporation: lead

Study Sites (8)

Hiroshima University Hospital

Hiroshima, Hiroshima, 734-8551, Japan

Location

Kagawa University Hospital

Kita-gun, Kagawa-ken, 761-0793, Japan

Location

Saitama Medical University Hospital

Iruma-gun, Saitama, 350-0495, Japan

Location

Saitama Medical Center

Kawagoe, Saitama, 350-8550, Japan

Location

Juntendo University Hospital

Bunkyo-ku, Tokyo, 113-8431, Japan

Location

NHO Tokyo Medical Center

Meguro-ku, Tokyo, 152-8902, Japan

Location

Kyorin University Hospital

Mitaka-shi, Tokyo, 181-8611, Japan

Location

Keio University Hospital

Shinjuku-ku, Tokyo, 160-8582, Japan

Location

Study Officials

• General Manager

  Tanabe Pharma Corporation

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 25, 2023
• First Posted: January 9, 2024
• Study Start: June 24, 2024
• Primary Completion: January 14, 2026
• Study Completion: January 14, 2026
• Last Updated: February 4, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

JP (8)